Methods of Treating or Preventing Migraine or Repetitive Occurrence of Common Migraine Headaches in a Subject Having Underlying Condition(s)

Abstract

The invention provides methods for treating primary disorders of mood and affect, including depressive disorders, anxiety and sleep disorders and CNS disorders comprising the administration of a neurotoxin.

1 . A method of treating migraine in a subject having an accompanying sleep disorder, the method comprising administering to the subject a pharmaceutical composition that comprises a botulinum toxin A in an amount effective to: a) treat the migraine in the subject; and b) decrease at least one symptom of the sleep disorder in the subject as compared to the symptom prior to the administrating;
 wherein the sleep disorder is delayed sleep phase disorder, advanced sleep phase disorder, or a combination thereof.   
     
     
         2 . The method of  claim 1 , wherein the subject further has atopic disease. 
     
     
         3 . The method of  claim 1 , wherein the subject suffers from a pain. 
     
     
         4 . The method of  claim 2 , wherein the subject suffers from a pain. 
     
     
         5 . The method of  claim 3 , wherein the pain is responsive to tactile stimulation. 
     
     
         6 . The method of  claim 4 , wherein the pain is responsive to tactile stimulation. 
     
     
         7 . The method of  claim 3 , wherein the treating results in relief from the pain. 
     
     
         8 . The method of  claim 4 , wherein the treating results in relief from the pain. 
     
     
         9 . The method of  claim 1 , wherein the treating prevents a migraine. 
     
     
         10 . The method of  claim 1 , wherein the administering comprises an injection. 
     
     
         11 . The method of  claim 10 , wherein the injection comprises at least two injection sites. 
     
     
         12 . The method of  claim 10 , wherein the injection is multifocal. 
     
     
         13 . The method of  claim 1 , wherein the administering is transdermal administering. 
     
     
         14 . The method of  claim 1 , wherein the botulinum toxin type A is from Hall strain  Clostridium botulinum.    
     
     
         15 . The method of  claim 1 , wherein the pharmaceutical composition further comprises a pharmaceutically acceptable carrier. 
     
     
         16 . A method of treating repetitive occurrence of common migraine headaches in a subject having an accompanying sleep disorder, the method comprising administering to the subject a pharmaceutical composition that comprises a botulinum toxin A in an amount effective to: a) treat the repetitive occurrence of common migraine headaches in the subject; and b) decrease at least one symptom of the sleep disorder in the subject as compared to the symptom prior to the administrating;
 wherein the sleep disorder is delayed sleep phase disorder, advanced sleep phase disorder, or any combination thereof.   
     
     
         17 . The method of  claim 16 , wherein the subject further has atopic disease. 
     
     
         18 . The method of  claim 16 , wherein the subject suffers from a pain. 
     
     
         19 . The method of  claim 17 , wherein the subject suffers from a pain. 
     
     
         20 . The method of  claim 18 , wherein the pain is responsive to tactile stimulation. 
     
     
         21 . The method of  claim 19 , wherein the pain is responsive to tactile stimulation. 
     
     
         22 . The method of  claim 18 , wherein the treating results in relief from the pain. 
     
     
         23 . The method of  claim 19 , wherein the treating results in relief from the pain. 
     
     
         24 . The method of  claim 16 , wherein the treating prevents a repetitive occurrence of common migraine. 
     
     
         25 . The method of  claim 16 , wherein the administering comprises an injection. 
     
     
         26 . The method of  claim 25 , the injection comprises at least two injection sites. 
     
     
         27 . The method of  claim 25 , wherein the injection is multifocal. 
     
     
         28 . The method of  claim 16 , wherein the administering is transdermal administering. 
     
     
         29 . The method of  claim 16 , wherein the botulinum toxin type A is from Hall strain  Clostridium botulinum.    
     
     
         30 . The method of  claim 16 , wherein the pharmaceutical composition further comprises a pharmaceutically acceptable carrier.